Current Indications and Future Landscape of Bispecific Antibodies for the Treatment of Lung Cancer

被引：2

作者：

Arasanz, Hugo ^{[1
,2
]}

Chocarro, Luisa ^{[3
]}

Fernandez-Rubio, Leticia ^{[3
]}

Blanco, Ester ^{[3
,4
]}

Bocanegra, Ana ^{[3
]}

Echaide, Miriam ^{[3
]}

Labiano, Ibone ^{[2
]}

Huerta, Ana Elsa ^{[2
]}

Alsina, Maria ^{[1
,2
]}

Vera, Ruth ^{[1
,2
]}

Escors, David ^{[3
]}

Kochan, Grazyna ^{[3
]}

机构：

[1] Hosp Univ Navarra, Med Oncol Dept, Inst Invest Sanitaria Navarra IdiSNA, Pamplona 31008, Spain

[2] Inst Invest Sanitaria Navarra IdiSNA, Oncobiona Grp, Navarrabiomed, Pamplona 31008, Spain

[3] Inst Invest Sanitaria Navarra IdiSNA, Oncoimmunol Grp, Navarrabiomed, Pamplona 31008, Spain

[4] Inst Invest Sanitaria Navarra IdiSNA, Div Gene Therapy & Regulat Gene Express, Ctr Invest Med Aplicada CIMA, Pamplona 31008, Spain

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2023年 / 24卷 / 12期

关键词：

lung cancer; bispecific; nanobodies; NSCLC; SCLC; targeted therapies; TYROSINE KINASE INHIBITORS; ACQUIRED-RESISTANCE; OPEN-LABEL; CHEMOTHERAPY; VEMURAFENIB; COBIMETINIB; MECHANISMS; NANOBODIES; NIVOLUMAB;

D O I：

10.3390/ijms24129855

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Bispecific antibodies are a promising type of therapy for the treatment of cancer due to their ability to simultaneously inhibit different proteins playing a role in cancer progression. The development in lung cancer has been singularly intense because of the increasingly vast knowledge of the underlying molecular routes, in particular, in oncogene-driven tumors. In this review, we present the current landscape of bispecific antibodies for the treatment of lung cancer and discuss potential scenarios where the role of these therapeutics might expand in the near future.

引用

页数：12

共 50 条

[1] Current status and future perspectives of bispecific antibodies in the treatment of lung cancer
Wang Wanying
Qiu Tianyu
Li Fei
Ren Shengxiang
中华医学杂志英文版, 2023, 136 (04)
[2] Current status and future perspectives of bispecific antibodies in the treatment of lung cancer
Wang, Wanying
Qiu, Tianyu
Li, Fei
Ren, Shengxiang
CHINESE MEDICAL JOURNAL, 2023, 136 (04) : 379 - 393
[3] Current landscape and future directions of bispecific antibodies in cancer immunotherapy
Wei, Jing
Yang, Yueyao
Wang, Gang
Liu, Ming
FRONTIERS IN IMMUNOLOGY, 2022, 13
[4] Bispecific antibodies in clinical practice: Understanding recent advances and current place in cancer treatment landscape
Verma, Vaibhav
Sharma, Geeti
CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 25 (01)
[5] The current and future landscape of radiotherapy for lung cancer
Louie, Alexander V.
Bahig, Houda
Moghanaki, Drew
TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S122 - S123
[6] T-cell redirecting bispecific antibodies in multiple myeloma: Current landscape and future directions
O'Neill, Chloe
van de Donk, Niels W. C. J.
EJHAEM, 2023, 4 (03): : 811 - 822
[7] Immunotherapy in Lung Cancer: Current Landscape and Future Directions
Mamdani, Hirva
Matosevic, Sandro
Khalid, Ahmed Bilal
Durm, Gregory
Jalal, Shadia I.
FRONTIERS IN IMMUNOLOGY, 2022, 13
[8] The present and future of bispecific antibodies for cancer therapy
Klein, Christian
Brinkmann, Ulrich
Reichert, Janice M.
Kontermann, Roland E.
NATURE REVIEWS DRUG DISCOVERY, 2024, 23 (04) : 301 - 319
[9] The present and future of bispecific antibodies for cancer therapy
Christian Klein
Ulrich Brinkmann
Janice M. Reichert
Roland E. Kontermann
Nature Reviews Drug Discovery, 2024, 23 : 301 - 319
[10] Bispecific antibodies for cancer immunotherapy: Current perspectives
Müller D.
Kontermann R.E.
BioDrugs, 2010, 24 (2) : 89 - 98

← 1 2 3 4 5 →